ArticlePloS one2026
Multi-omics analysis and functional validation of CHEK1 as an independent prognostic biomarker in Pancreatic cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer is a highly aggressive tumor with a poor prognosis due to challenging early diagnosis and limited treatment options. CHEK1, a crucial cell cycle regulator, is important in tumor development, but its role in pancreatic cancer remains under-researched in terms of expression, function, and regulation.
objectiveTo study the effect of CHEK1 on proliferation, migration and cell cycle of pancreatic cancer, and to construct a prognostic prediction model to investigate the effect of CHEK1 on the prognosis of pancreatic cancer.
methodsWe conducted a systematic investigation into the expression characteristics and biological functions of CHEK1 in pancreatic cancer, utilizing an integration of bioinformatics analyses and in vitro experiments. Initially, we performed an in-depth analysis of CHEK1 expression profiles and their clinical significance in pancreatic cancer, drawing on data from several public databases, including UALCAN, TNMplot, and TISIDB. Subsequently, we validated the impact of CHEK1 on the malignant biological behaviors of pancreatic cancer cells, specifically focusing on proliferation and migration, through a series of in vitro cellular experiments.
resultsThe findings revealed that CHEK1 expression levels were significantly upregulated in pancreatic cancer tissues, which correlated positively with tumor pathological grade. KEGG pathway enrichment analysis further indicated that CHEK1 exerts critical regulatory functions across multiple oncogenic pathways, including cellular proliferation, G2/M checkpoint control, DNA replication, and DNA damage repair. In vitro experimental demonstrated that CHEK1 overexpression substantially increased both the proliferative progression and migratory capacity of pancreatic cancer cells.
conclusionsOur study indicates that high CHEK1 expression could be an independent prognostic marker for pancreatic cancer and may drive cancer progression by influencing DNA replication and G2/M checkpoint pathways. These insights offer a foundation for future research and targeted precision therapy involving CHEK1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.